Chemotherapeutic errors in hospitalised cancer patients: Attributable damage and extra costs

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ranchon, Florence ^a   Salles, Gilles ^a   Späth, Hans Martin ^b   Schwiertz, Vérane ^c   Vantard, Nicolas ^c   Parat, Stéphanie ^c   Broussais, Florence ^c   You, Benoît ^a   Tartas, Sophie ^c   Souquet, Pierre J ^c   Dussart, Claude ^a   Falandry, Claire ^a   Henin, Emilie ^a   Freyer, Gilles ^a   Rioufol, Catherine ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE LYON   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; RALTITREXED; RITUXIMAB; TRASTUZUMAB; VINBLASTINE; VINCRISTINE; VINDESINE; PRESCRIPTION DRUG;

ARTICLE; CANCER PATIENT; COST BENEFIT ANALYSIS; FRANCE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MALIGNANT NEOPLASTIC DISEASE; MEDICATION ERROR; MORTALITY; PATIENT MONITORING; PATIENT SAFETY; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; UNIVERSITY HOSPITAL; COST; ECONOMICS; NEOPLASM; STATISTICS; TEACHING HOSPITAL;

ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; FRANCE; HOSPITALS, TEACHING; HUMANS; MEDICATION ERRORS; NEOPLASMS; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES;

EID: 80455158285     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-478     Document Type: Article

References (33)

1. Kohn LT, Corrigan JM, Donaldson MS. To err is human: Building a safer health system 1999, Washington DC: National Academy Press.
2. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, Newhouse JP, Weiler PC, Hiatt HH. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991, 324:370-376. 10.1056/NEJM199102073240604, 1987460.
3. National coordinating council on medication error reporting and prevention. , http://www.nccmerp.org/aboutMedErrors.html
4. Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, Pamer C. Retrospective analysis of mortalities associated with medication error. Am J Health Syst Pharm 2001, 58:1835-1834.
5. Klys M, Konopka T, Scislowski M, Kowalski P. Fatality involving vinblastine overdose as a result of a complex medical error. Cancer Chemother Pharmacol 2007, 59:89-95.
6. Al Ferayan A, Russell NA, Wohaibi MA, Awada A, Scherman B. Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection. Child's Nerv Syst 1999, 15:87-89. 10.1007/s003810050338, 22073860.
7. Ettinger LJ. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982, 50:444-450. 10.1002/1097-0142(19820801)50:3<444::AID-CNCR2820500311>3.0.CO;2-#, 6178493.
8. Chu G, Mantin R, Shen YM, Baskett G, Sussman H. Massive cisplatin overdose by accidental substitution for carboplatin. Cancer 1993, 72:3707-3714. 10.1002/1097-0142(19931215)72:12<3707::AID-CNCR2820721224>3.0.CO;2-U, 8252487.
9. Tournel G, Bécart-Robert A, Courtin P, Hédouin V, Gosset D. Fatal accidental intrathecal injection of vindesine. J Forensic Sci 2006, 51:1166-1168. 10.1111/j.1556-4029.2006.00241.x, 17018103.
10. Dettmeyer R, Driever F, Becker A, Wiestler OD, Madea B. Fatal myeloencephalopathy due to accidental intrathecal vincristine administration: a report of two cases. Forensic Sci Int 2001, 122:60-64. 10.1016/S0379-0738(01)00394-2, 11587867.
11. Kwack EK, Kim DJ, Park TI, Cho KR, Kwon IH, Sohn YK. Neural toxicity induced by accidental intrathecal vincristine administration. J Korean Med Sci 1999, 14:688-692. 3054437, 10642952.
12. Mortensen ME, Cecalupo AJ, Lo WD, Egorin MJ, Batley R. Inadvertent intrathecal injection of daunorubicin with fatal outcome. Med Pediatr Oncol 1992, 20:249-253. 10.1002/mpo.2950200315, 1574039.
13. ASHP Council on Professional Affairs ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Health Syst Pharm 2002, 59:1648-1668. ASHP Council on Professional Affairs.
14. Cohen MR, Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm 1996, 53:737-746.
15. Fischer DS, Alfano S, Knobf MT, Donovan C, Beaulieu N. Improving the cancer chemotherapy use process. J Clin Oncol 1996, 14:3148-3155.
16. Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M, Bonelli KR, McCorkle MR, . American Society of Clinical Oncology American society of clinical oncology/oncology nursing society chemotherapy administration safety standards. J Clin Oncol 2009, 27:5469-75. 10.1200/JCO.2009.25.1264, 19786650, American Society of Clinical Oncology.
17. Surbone A, Rowe M, Gallagher TH. Confronting medical errors in oncology and disclosing them to cancer patients. J Clin Oncol 2007, 25:1463-7. 10.1200/JCO.2006.09.9218, 17442988.
18. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL. The cost of adverse drug events in hospitalized patients. JAMA 1997, 277:307-311. 10.1001/jama.277.4.307, 9002493.
19. Institute of Medicine. Report brief: Preventing medication errors 2006, National Academy Press., http://iom.edu/~/media/Files/Report%20Files/2006/Preventing-Medication-Errors-Quality-Chasm-Series/medicationerrorsnew.ashx
20. Methodological guide production of summaries of stay in medicine, surgery and obstetrics. Agence Technique de l'Information sur l'Hospitalisation. , http://www.atih.sante.fr/index.php?id=000240007EFF
21. Arrêté du 27 février 2007 relatif aux ressources d'assurances maladies des établissements de santé exerçant une activité de médecine, chirurgie, obstétrique et odontologie. Journal Officiel république Française du 4 mars 2007, , http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000271206&dateTexte=
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
23. Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA 1997, 277:312-317. 10.1001/jama.277.4.312, 9002494.
24. Rubin G, George A, Chinn DJ, Richardson C. Errors in general practice: development of an error classification and pilot study of a method for detecting errors. Qual Saf Health Care 2003, 12:443-447. 10.1136/qhc.12.6.443, 1758031, 14645760.
25. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009, 124:722-728. 10.1002/ijc.23991, 18989899.
26. Grangeasse L, Fagnoni-Legat C, Chaigneau L, Medjoub M, Larosa F, Bracco-Nolin CH, Woronoff-Lemsi MC, Limat S. Computerized prescribing of standardized chemotherapy schedules: residual medication errors and pharmaceutical interventions. J Pharm Clin 2006, 25(1):33-38.
27. Shulman R, Singer M, Goldstone J, Bellingan G. Medication errors: a prospective cohort study of hand-written and computerised physician order entry in the intensive care unit. Crit Care 2005, 9:516-521.
28. Colpaert K, Claus B, Somers A, Vandewoude K, Robays H, Decruyenaere J. Impact of computerized physician order entry on medication prescription errors in the intensive care unit: a controlled cross-sectional trial. Crit Care 2006, 10:R21. 10.1186/cc3983, 1550814, 16469126.
29. Finkelstein JB. E-prescribing first step to improved safety. J Nat Cancer Inst 2006, 98:1763-1764. 10.1093/jnci/djj519, 17179476.
30. Tissot E, Cornette C, Limat S, Mourand JL, Becker M, Etievent JP, Dupond JL, Jacquet M, Woronoff-Lemsi MC. Observational study of potential risk factors of medication administration errors. Pharm World Sci 2003, 25:264-268.
31. Tissot E, Cornette C, Demoly P, Jacquet M, Barale F, Capellier G. Medication errors at the administration stage in an intensive care unit. Intensive Care Med 1999, 25:353-359. 10.1007/s001340050857, 10342507.
32. Gruwez B, Penaud JF, Lecante V, Lopez I, Dauphin A. Analysis of a manufacturing process example for cytotoxics in a hospital pharmacy. J Pharm Clin 2001, 20:145-148.
33. Limat S, Drouhin JP, Demesmay K, Tissot E, Jacquet M, Woronoff-Lemsi MC. Incidence and risk factors of preparation errors in a centralized cytotoxic preparation unit. Pharm World Sci 2001, 23:102-106. 10.1023/A:1011252132478, 11468873.